{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-068659","form_type":"8-K","ticker":"ACXP","cik":"0001736243","company_name":"Acurx Pharmaceuticals, Inc.","filed_at":"2025-07-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.838468+00:00","generated_at":"2026-05-18T05:59:11.127529+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Acurx shareholders approve reverse split, equity plan increase, and director elections at annual meeting","bullets":["All six proposals passed at July 17 meeting; 74.38% of shares represented.","Reverse stock split authorized at ratio 1:10 to 1:30; board to set timing and exact ratio.","2021 Equity Plan share reserve increased from 177,448 to 2,677,448 shares.","Directors Sailer and Harrison re-elected; auditor CohnReznick ratified; warrant exercise and ELOC approved for Nasdaq compliance."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-068659","json":"https://secwatch.observer/filing/0001104659-25-068659.json","markdown":"https://secwatch.observer/filing/0001104659-25-068659.md","text":"https://secwatch.observer/filing/0001104659-25-068659.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1736243/000110465925068659/0001104659-25-068659-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1736243/000110465925068659/tm2521097d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T05:59:11.127529+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}